Clinical Trial SuccessA Ph3 study of denifanstat that Sagimet's partner conducted in China met all primary and secondary endpoints with P<0.0001 for all efficacy measures, showing higher placebo-adjusted overall treatment success rate and lesion reductions vs. two branded acne therapies.
Financial StabilitySagimet Biosciences has enough cash, $135 million, to support operations through the completion of Phase 1 trials, indicating financial stability.
Partnership And DevelopmentGrowing partnership interest in MASH program.